• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Sep. 30, 2015

View Archived Issues

Heaven's gate? Astellas Pharma's potential $500M tie adds Chromocell pain voltage

Chromocell Corp. CEO Christian Kopfli told BioWorld Today that payments in his firm's potential $500 million deal with Astellas Pharma Inc. are "evenly spaced" along the development path for the oral Nav1.7 inhibitor CC8464 to treat neuropathic pain, for which trials are expected to start next year. Read More

Start-up Therachon raises $35M to take on Biomarin in achondroplasia

DUBLIN – French start-up Therachon SAS raised $35 million in a series A round to take forward a new treatment for achondroplasia, an autosomal dominant bone growth disorder that causes short-limbed dwarfism. Read More

Mum's the word as Corvus attracts $75M series B for checkpoint play

Corvus Pharmaceuticals Inc., which was quietly incorporated late last year with a $33.5 million series A, doubled down in its second raise, closing a $75 million series B from a syndicate led by Rock Springs Capital Management that included Fidelity Management and Research Co., Blackrock, accounts managed by T. Rowe Price, Jennison Associates on behalf of certain clients, Roche Venture Fund, Cormorant Asset Management, Sphera Funds Management, Venbio Select and Cowen Private Investments. Read More

Pricing maelstrom threatens to suck in another drugmaker

Hear that sucking sound? It's getting louder as the maelstrom Turing Pharmaceuticals LLC recently churned up over drug prices threatens to engulf another biopharma company. Read More

Targeted CV therapy start-up Myokardia files for initial public offering

Myokardia Inc., which is targeting rare, genetically driven forms of heart failure, elected to brave a blustery market for biopharma, filing to raise up to $86.3 million through an IPO on Nasdaq. Read More

Urinary excretion developed for stem cell-generated kidneys

HONG KONG — For the first time, biologists have successfully developed functioning whole kidneys with a urinary excretion pathway from human stem cell-generated embryonic kidneys, Japanese researchers reported in the Proceedings of the National Academy of Sciences. Read More

Genova emerges with goal to become largest insulin maker in China

HONG KONG – Genova Biotechnology Co. Ltd. is aiming to be the largest insulin maker in China, and is starting construction on a $1 billion manufacturing facility in Changzhou National Hi-tech District this month. Read More

Regulatory front

The Center for Medicare and Medicaid Innovation (CMMI) plans to roll out an enhanced medication therapy management (MTM) model to test strategies to improve Part D medication use among Medicare beneficiaries. Read More

Stock movers

Read More

Financings

Asceneuron SA, of Lausanne, Switzerland, said it closed a series A financing of CHF30 million (US$30.6 million) led by Sofinnova Partners. Read More

Other news to note

Carsgen Therapeutics, of Shanghai, said it entered a five year research and development agreement with the Shanghai Cancer Institute for the advancement of its CAR-T cancer immunotherapeutics. Read More

In the clinic

Novan Therapeutics, of Durham, N.C., reported that its topical nitric oxide drug candidate for the treatment of acne vulgaris, SB-204, demonstrated a statistically significant 20 percent differential vs. vehicle in the percent change of non-inflammatory (white heads and black heads) and inflammatory (larger red bumps and pustules) lesions at week 12 of a phase IIb study. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • Robert Paris, vice president, Moderna

    Moderna expands mRNA tech to latent viruses, cancer, rare disease

    BioWorld
    Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe